Top

Published in:

Open Access 01-03-2015 | Review Article

Diagnosis and treatment of Ewing sarcoma of the bone: a review article

Author: Toshifumi Ozaki

Published in: Journal of Orthopaedic Science | Issue 2/2015

Abstract

Ewing sarcoma (ES) is rare in Japanese people, and only 30–40 patients develop the disease annually. To diagnose ES, molecular techniques that aim to detect characteristic fusion genes are commonly used in combination with conventional histological and immunohistochemical examinations. The treatment strategy for ES is characterized by multi-disciplinary collaboration between pediatric oncologists, medical oncologists, radiation oncologists, and orthopedic surgeons. In recent years, numerous large-scale national or international multi-institutional studies of ES have been performed. Pre- and postoperative intensive systemic chemotherapy with multiple anticancer drugs is the standard treatment method for ES. Depending on the obtained surgical margin, postoperative radiation might also be performed. If preoperative radiological examinations indicate that surgical excision would be difficult, preoperative radiation can be administered. As the treatment outcomes of ES have improved, late complications and secondary malignancies have become a problem. After treatment, patients with ES require very long-term follow-up in order to detect secondary malignancies and growth-related musculoskeletal complications.

Jaffe R, Santamaria M, Yunis EJ, Tannery NH, Agostini RM Jr, Medina J, Goodman M. The neuroectodermal tumor of bone. Am J Surg Pathol. 1984;8(12):885–98.CrossRefPubMed

Carlei F, Polak JM, Ceccamea A, Marangos PJ, Dahl D, Cocchia D, Michetti F, Lezoche E, Speranza V. Neuronal and glial markers in tumours of neuroblastic origin. Virchows Arch A Pathol Anat Histopathol. 1984;404(3):313–24.CrossRefPubMed

Hashimoto H, Enjoji M, Nakajima T, Kiryu H, Daimaru Y. Malignant neuroepithelioma (peripheral neuroblastoma). A clinicopathologic study of 15 cases. Am J Surg Pathol. 1983;7(4):309–18.CrossRefPubMed

de Alava E, Lessnick SL, Sorensen PH. Ewing sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon: WHO Press; 2013. p. 305–9.

Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, Aurias A, Thomas G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–5.CrossRefPubMed

Rosen G, Juergens H, Caparros B, Nirenberg A, Huvos AG, Marcove RC. Combination chemotherapy (T-6) in the multidisciplinary treatment of Ewing's sarcoma. Natl Cancer Inst Monogr. 1981;(56):289–99.

Rosen G. Current management of Ewing’s sarcoma. Prog Clin Cancer. 1982:267–82.

Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P, Askin FB, Kissane JM, Pritchard DJ, Herrmann J, Neff J, Makley JT, Gilula L. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8(10):1664–74.PubMed

Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, Cangir A, Tefft M, Evans R, Thomas P. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8(9):1514–24.PubMed

10.

Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.CrossRefPubMed

11.

Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Childrenʼs Oncology Group. J Clin Oncol. 2012;30(33):4148–54.CrossRefPubMedCentralPubMed

12.

Jürgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, Treuner J, Voute T, Winkelmann W, Winkler K, Göbel U. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988;61(1):23–32.CrossRefPubMed

13.

Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jürgens H. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19(6):1818–29.PubMed

14.

Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Kohler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H. European Intergroup Cooperative Ewing’s Sarcoma S. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26(27):4385–93.CrossRefPubMed

15.

Cripe TP. Ewing sarcoma: an eponym window to history. Sarcoma. 2011;2011:457532. doi:10.1155/2011/457532 (Epub 2010 Dec 1).CrossRefPubMedCentralPubMed

16.

Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Berard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014;32(23):2440–8.CrossRefPubMed

17.

Lücke A. Beiträge zur Geschwulstlehre. Virchows Arch Pathol Anat. 1866;35:524–39.CrossRef

18.

Huvos AG. Ewing’s sarcoma. In: Huvos AG, editor. Bone tumor diagnosis, treatment, and prognosis. Philadelphia: WB Saunders; 1991. p. 523–52.

19.

Stou AP. A tumor of the ulnar nerve. Proc NY Pathol Soc. 1918;18:2–12.

20.

Stou AP, Murray MD. Neuroephithelioma of the radial nerve with a study of its behavior in vitro. Rev Can Biol. 1942;1:651–9.

21.

Ewing J. Diffuse endothelioma of bone. Proc NY Path Soc. 1921;21:17–24.

22.

Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing’s sarcoma. Cancer. 1975;36(1):240–51.CrossRefPubMed

23.

Nesbitt KA, Vidone RA. Primitive neuroectodermal tumor (neuroblastoma) arising in sciatic nerve of a child. Cancer. 1976;37(3):1562–70.CrossRefPubMed

24.

Askin FB, Rosai J, Sibley RK, Dehner LP, McAlister WH. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer. 1979;43(6):2438–51.CrossRefPubMed

25.

Turc-Carel C, Philip I, Berger MP, Philip T, Lenoir G. Chromosomal translocation (11;22) in cell lines of Ewing’s sarcoma. C R Seances Acad Sci III. 1983;296(23):1101–3.PubMed

26.

Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, Thiery JP, Olschwang S, Philip I, Berger MP, Philip T, Lenoir GM, Mazabraud A. Chromosomes in Ewing’s sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet. 1988;32(2):229–38.CrossRefPubMed

27.

JOA Musculoskeletal Tumor Committee. Bone Tumor Registry in Japan. 2011.

28.

JOA Musculoskeletal Tumor Committee. Soft Tissue Tumor Registry in Japan. 2011.

29.

Li FP, Tu JT, Liu FS, Shiang EL. Rarity of Ewing’s sarcoma in China. Lancet. 1980;1(8180):1255.CrossRefPubMed

30.

Jensen RD, Drake RM. Rarity of Ewing’s tumour in negroes. Lancet. 1970;1(7650):777.CrossRefPubMed

31.

Fraumeni JF Jr, Glass AG. Rarity of Ewing’s sarcoma among US negro children. Lancet. 1970;1(7642):366–7.CrossRefPubMed

32.

Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda: National Cancer Institute, SEER Program; 1999. NIH Pub No 99-4649.

33.

Patterson FR, Basra SK. Ewing’s sarcoma. In: Schwartz HS, editor. Orthopaedic knowledge update: musculoskeletal tumors 2. Rosemont: American Academy of Orthopaedic Surgeons; 2007. p. 175–83.

34.

Gyorke T, Zajic T, Lange A, Schafer O, Moser E, Mako E, Brink I. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun. 2006;27(1):17–24.CrossRefPubMed

35.

Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991;67(7):1886–93.CrossRefPubMed

36.

Olsen SH, Thomas DG, Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol. 2006;19(5):659–68.CrossRefPubMed

37.

Nascimento AG, Unii KK, Pritchard DJ, Cooper KL, Dahlin DC. A clinicopathologic study of 20 cases of large-cell (atypical) Ewing’s sarcoma of bone. Am J Surg Pathol. 1980;4(1):29–36.CrossRefPubMed

38.

Ozaki T, Nakagawa Y, Yoshida A, Numoto K, Sugihara S, Kunisada T, Hamazaki S, Inoue H. Amplification of MYCL in atypical Ewing tumor analysis of metaphase and microarray comparative genomic hybridization. Cancer Genomic Proteomic. 2004;1:275–82.

39.

Folpe AL, Goldblum JR, Rubin BP, Shehata BM, Liu W, Dei Tos AP, Weiss SW. Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol. 2005;29(8):1025–33.PubMed

40.

Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA. EWS-erg and EWS-Fli1 fusion transcripts in Ewing’s sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest. 1994;94(2):489–96.CrossRefPubMedCentralPubMed

41.

Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor. ERG. Nat Genet. 1994;6(2):146–51.CrossRef

42.

Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN. A variant Ewing’s sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10(6):1229–34.PubMed

43.

Kaneko Y, Yoshida K, Handa M, Toyoda Y, Nishihira H, Tanaka Y, Sasaki Y, Ishida S, Higashino F, Fujinaga K. Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Gene Chromosome Cancer. 1996;15(2):115–21.CrossRef

44.

Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing’s sarcoma. Biochem Biophys Res Commun. 1996;219(2):608–12.CrossRefPubMed

45.

Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, Delattre O. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997;14(10):1159–64.CrossRefPubMed

46.

Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S, Hoffmann C, Hillmann A, Wai D, Schäf er KL, Böcker W, Jürgens H, Winkelmann W, Dockhorn-Dworniczak B. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer. 2001;32(2):164–71.CrossRefPubMed

47.

Kunisada T, Yoshida A, Morimoto Y, Itani T, Yanai H, Sugihara S, Ozaki T. Fusion gene assay in the treatment of bone and soft tissue tumors. Proceedings of the 43rd Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association. 2010;84:S977 (in Japanese).

48.

Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I, Smith TL, Jürgens H, Gadner H, Kovar H. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol. 1996;14(4):1245–51.PubMed

49.

de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing’s sarcoma. J Clin Oncol. 1998;16(4):1248–55.PubMed

50.

Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, Zoubek A, Dockhorn-Dworniczak B, Juergens H, Wunder JS, Andrulis IL, Malik R, Sorensen PH, Womer RB, Barr FG. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing’s sarcoma. J Clin Oncol. 1999;17(6):1809–14.PubMed

51.

Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslbock M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H. Impact of EWS-ETS fusion type on disease progression in Ewing’s sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-EWING 99 trial. J Clin Oncol. 2010;28(12):1982–8.CrossRefPubMed

52.

Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, Tanaka K, Tsuchiya H, Matsumine A, Yabe H. Japanese Musculoskeletal Oncology G. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer. 2007;109(4):767–75.CrossRefPubMed

53.

Wexler LH, DeLaney TF, Tsokos M, Avila N, Steinberg SM, Weaver-McClure L, Jacobson J, Jarosinski P, Hijazi YM, Balis FM, Horowitz ME. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing’s sarcoma family of tumors. Cancer. 1996;78(4):901–11.CrossRefPubMed

54.

Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier HE. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(15):2536–41.CrossRefPubMedCentralPubMed

55.

Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, Baker DL, Davis JH, Gerbing RB, Grovas A, Herzog CE, Lindsley KL, Liu-Mares W, Nachman JB, Sieger L, Wadman J, Gorlick RG. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol. 2001;19(11):2812–20.PubMed

56.

Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jürgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.CrossRefPubMed

57.

Dunst J, Sauer R, Burgers JM, Hawliczek R, Kurten R, Winkelmann W, Salzer-Kuntschik M, Muschenich M, Jürgens H. Radiation therapy as local treatment in Ewing’s sarcoma. Results of the Cooperative Ewing’s Sarcoma Studies CESS 81 and CESS 86. Cancer. 1991;67(11):2818–25.CrossRefPubMed

58.

Ozaki T, Hillmann A, Hoffmann C, Rube C, Blasius S, Dunst J, Jürgens H, Winkelmann W. Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer. 1996;78(4):892–900.CrossRefPubMed

59.

Bacci G, Toni A, Avella M, Manfrini M, Sudanese A, Ciaroni D, Boriani S, Emiliani E, Campanacci M. Long-term results in 144 localized Ewing’s sarcoma patients treated with combined therapy. Cancer. 1989;63(8):1477–86.CrossRefPubMed

60.

Wilkins RM, Pritchard DJ, Burgert EO Jr. Unni KK. Ewing’s sarcoma of bone. Experience with 140 patients. Cancer. 1986;58(11):2551–5.CrossRefPubMed

61.

Kawaguchi N, Ahmed AR, Matsumoto S, Manabe J, Matsushita Y. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res. 2004;419:165–72.CrossRefPubMed

62.

Schuck A, Ahrens S, Paulussen M, Kuhlen M, Konemann S, Rube C, Winkelmann W, Kotz R, Dunst J, Willich N, Jürgens H. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55(1):168–77.CrossRefPubMed

63.

Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Frohlich B, Winkelmann W, Zoubek A, Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9(3):275–81.CrossRefPubMed

64.

Bolling T, Schuck A, Paulussen M, Dirksen U, Ranft A, Konemann S, Dunst J, Willich N, Jürgens H. Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol. 2008;184(4):193–7.CrossRefPubMed

65.

Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, Tsuji H, Ito H, Tsujii H. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2009;75(4):1105–10.CrossRefPubMed

66.

Tsuchiya H, Wan SL, Sakayama K, Yamamoto N, Nishida H, Tomita K. Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br. 2005;87(2):218–25.CrossRefPubMed

67.

Murakami H, Demura S, Kato S, Nishida H, Yoshioka K, Hayashi H, Inoue K, Ota T, Shinmura K, Yokogawa N, Fang X, Tsuchiya H. Increase of IL-12 following reconstruction for total en bloc spondylectomy using frozen autografts treated with liquid nitrogen. PLoS One. 2013;8(5):e64818.CrossRefPubMedCentralPubMed

68.

Hoffmann C, Ahrens S, Dunst J, Hillmann A, Winkelmann W, Craft A, Gobel U, Rube C, Voute PA, Harms D, Jürgens H. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer. 1999;85(4):869–77.CrossRefPubMed

69.

Akiyama T, Clark JC, Miki Y, Choong PF. The non-vascularised fibular graft: a simple and successful method of reconstruction of the pelvic ring after internal hemipelvectomy. J Bone Joint Surg Br. 2010;92(7):999–1005.CrossRefPubMed

70.

Ozaki T, Hillmann A, Winkelmann W. Treatment outcome of pelvic sarcomas in young children: orthopaedic and oncologic analysis. J Pediatr Orthop. 1998;18(3):350–5.PubMed

71.

Gebert C, Wessling M, Hoffmann C, Roedl R, Winkelmann W, Gosheger G, Hardes J. Hip transposition as a limb salvage procedure following the resection of periacetabular tumors. J Surg Oncol. 2011;103(3):269–75.CrossRefPubMed

72.

Rödl RW, Hoffmann C, Gosheger G, Leidinger B, Jürgens H, Winkelmann W. Ewing’s sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol. 2003;83(3):154–60.CrossRefPubMed

73.

Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005;44(4):338–47.CrossRefPubMed

74.

Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006;47(6):795–800.CrossRefPubMed

75.

Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–9.CrossRefPubMed

76.

Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Gobel U, Kremens B, Folsch UR, Aulitzky WE, Voute PA, Zoubek A, Jürgens H. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol. 2001;12(11):1619–30.CrossRefPubMed

77.

Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983–2006). Cancer. 2012;118(20):5050–9.CrossRefPubMed

78.

Keir ST, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2012;59(3):586–8.CrossRefPubMedCentralPubMed

79.

Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(8):1325–32.CrossRefPubMedCentralPubMed

80.

Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children’s Oncology Group study. Clin Cancer Res. 2005;11(2.1):672–7.

81.

Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur J Cancer. 2012;48(4):579–85.CrossRefPubMed

Title: Diagnosis and treatment of Ewing sarcoma of the bone: a review article
Author: Toshifumi Ozaki
Publication date: 01-03-2015
Publisher: Springer Japan
Published in: Journal of Orthopaedic Science / Issue 2/2015
Print ISSN: 0949-2658
Electronic ISSN: 1436-2023
DOI: https://doi.org/10.1007/s00776-014-0687-z

At a glance: The STEP trials

Springer Medicine

Diagnosis and treatment of Ewing sarcoma of the bone: a review article

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Analysis of chronic low back pain with magnetic resonance imaging T2 mapping of lumbar intervertebral disc

Preliminary study of the patterns and physical risk factors of work-related musculoskeletal disorders among academicians in a higher learning institute

Monitoring of progression of nonsurgically treated rotator cuff tears by magnetic resonance imaging

Graft diameter does not influence primary stability of ulnar collateral ligament reconstruction of the elbow

Proposition of a protocol to evaluate upper-extremity functional deficits and compensation mechanisms: application to elbow contracture

Venous thromboembolism associated with lower limb fractures after trauma: dilemma and management